Drug Profile

Research programme: RNA based therapeutics - miRecule

Alternative Names: MIR 101; MIR-101 - miRecule; miR-30-5p mimic

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator miRecule
Class Antineoplastics; Antivirals; MicroRNAs; Oligoribonucleotides; RNA; RNA binding proteins
Mechanism of Action MicroRNA modulators; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

No development reported COVID 2019 infections; Head and neck cancer; HIV infections

28 Jun 2025 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
28 Jun 2025 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)
07 Jun 2021 miRecule has patent protection for RNA chemistry to develop RNA therapeutics before May 2021 (miRecule website, June 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com